Tauroursodeoxycholic acid (TUDCA) is a hydrophilic, taurine-conjugated bile acid that has been studied in cell culture and animal models for its capacity to delay photoreceptor cell death in retinal degeneration. Across multiple model systems — including inherited degenerations driven by genetic mutations and acute injury from retinal detachment — researchers have found that TUDCA can reduce the pace of rod and cone loss and, in some cases, preserve measurable visual function.
This body of research is encouraging but remains predominantly preclinical. The studies summarized here are animal model experiments; large-scale randomized controlled trials in humans with retinal degeneration are not yet available. Nothing in this article should be interpreted as a recommendation to self-treat any eye condition with TUDCA, and anyone considering supplementation for an ocular condition should consult an ophthalmologist before proceeding.
Key Takeaways
- In multiple preclinical animal models — including rd1, rd10, and P23H rodents and Rpgr knockout mice — TUDCA slowed photoreceptor degeneration and preserved retinal function relative to untreated controls.
- Proposed mechanisms include inhibition of ER stress, suppression of the mitochondrial apoptosis pathway, antioxidant activity, and promotion of RPE phagocytosis via MerTK activation.
- TUDCA has shown photoreceptor-protective effects in models of both chronic inherited retinal degeneration and acute injury from retinal detachment.
- Subcutaneous delivery has been explored as a systemic route for reaching retinal tissue, with cone photoreceptor rescue demonstrated in one model, but no approved human therapy for retinal degeneration has emerged from this research.
- All reviewed evidence is preclinical; large randomized human trials in retinal degeneration have not been conducted, and TUDCA is not a substitute for established ophthalmic care.
How TUDCA May Protect Photoreceptors: Proposed Mechanisms
Photoreceptors are among the most metabolically demanding cells in the body, making them vulnerable to multiple converging injury pathways. TUDCA is thought to act at several of these simultaneously. Its best-documented effect is suppression of endoplasmic reticulum (ER) stress — a state in which misfolded proteins accumulate inside the cell and trigger programmed cell death. Many inherited retinal dystrophies, including those caused by mutations in rhodopsin, involve chronic ER stress, and researchers have proposed that TUDCA acts as a chemical chaperone that helps restore ER homeostasis [1].
TUDCA also inhibits the intrinsic (mitochondrial) apoptosis pathway by stabilizing the mitochondrial membrane and reducing cytochrome c release. This is relevant because photoreceptor death in degenerating retinas typically proceeds via apoptosis rather than necrosis. Additionally, the molecule demonstrates antioxidant properties: one study found that TUDCA protected against oxidative stress-induced retinal degeneration, with effects comparable to those of bilirubin, another endogenous bile constituent [3]. Research examining natural compounds including bear bile derivatives has also pointed to anti-apoptotic and anti-inflammatory signaling as contributors to photoreceptor survival in degeneration models [8].
Evidence from Classic Inherited Degeneration Models: rd1, rd10, and P23H
The rd1 and rd10 mouse strains carry mutations in the Pde6b gene that cause rapid rod photoreceptor degeneration beginning in the second week of life, making them widely used benchmarks for testing neuroprotective compounds. In rd10 mice, TUDCA administration preserved photoreceptor structure and function through postnatal day 30, with treated animals showing better-retained outer nuclear layer thickness and electroretinogram (ERG) amplitudes compared with untreated controls [2]. A separate study in rd1 mice confirmed that TUDCA protected both retinal function and structure, further supporting its potential in this class of genetic model [9].
The P23H transgenic rat is a model of autosomal dominant retinitis pigmentosa caused by a proline-to-histidine substitution at position 23 of rhodopsin — a mutation also found in human patients. Treatment with TUDCA significantly slowed photoreceptor degeneration in these animals, with preserved outer segment morphology and reduced apoptosis detected in the outer nuclear layer [4]. Results across these three models suggest that TUDCA’s protective effects are not restricted to a single genetic mutation but may reflect a broader neuroprotective mechanism acting downstream of the initiating cellular insult.
X-Linked Retinitis Pigmentosa and Cone Photoreceptor Rescue
X-linked retinitis pigmentosa caused by mutations in the RPGR (retinitis pigmentosa GTPase regulator) gene accounts for a substantial proportion of severe retinal degeneration cases. In Rpgr knockout mice, TUDCA administration was associated with neuroprotective effects including reduced photoreceptor apoptosis and partial preservation of outer nuclear layer structure, pointing to a role for ER stress and mitochondrial pathways in this genetically distinct model [10].
Cone photoreceptors — responsible for daytime and color vision — are often lost secondarily after rod death in retinitis pigmentosa and are a key preservation target. A study using subcutaneous delivery of TUDCA in a degenerative retina model demonstrated that this systemic route of administration could rescue cone photoreceptors, maintaining structural integrity and suggesting that systemic dosing may be a viable approach for reaching retinal tissue [11]. Leber congenital amaurosis (LCA), a severe early-onset inherited retinal dystrophy, has also been discussed as a potential target for anti-apoptotic neuroprotective strategies given the central role of photoreceptor apoptosis in its progression [6].
TUDCA in Retinal Detachment-Induced Photoreceptor Loss
Retinal detachment separates photoreceptors from the retinal pigment epithelium (RPE) that supports them metabolically, triggering rapid apoptotic cell death. In an experimental model of retinal detachment, TUDCA administration significantly reduced photoreceptor apoptosis, with treated eyes retaining more cells in the outer nuclear layer compared with untreated controls [5]. This finding is clinically relevant because even after successful surgical reattachment, patients often experience incomplete visual recovery, partly attributable to photoreceptor loss during the detachment interval.
A 2026 review of neurodegeneration and neuroprotection in retinal detachment contextualized these findings within the broader literature, noting that compounds targeting apoptotic and stress-response pathways represent a promising class of adjuncts to mechanical repair [12]. TUDCA’s capacity to act on multiple apoptotic entry points makes it mechanistically relevant to the acute injury setting, though clinical translation in humans has not yet been demonstrated.
TUDCA and Retinal Pigment Epithelium Function: The MerTK Connection
The retinal pigment epithelium performs daily phagocytosis of shed photoreceptor outer segment discs — a housekeeping function essential to long-term photoreceptor survival. Defects in this process underlie several inherited retinal degenerations. One study found that TUDCA promotes RPE phagocytosis through activation of MerTK (Mer proto-oncogene tyrosine kinase), a receptor critical to outer segment engulfment [7]. This mechanism adds a dimension beyond direct apoptosis suppression: TUDCA may also help maintain the supportive RPE layer on which photoreceptors depend for their ongoing viability.
MerTK mutations are associated with retinitis pigmentosa in humans, and enhancing MerTK signaling in RPE cells is considered a plausible therapeutic direction. If TUDCA’s MerTK-activating effect extends to disease settings, it could represent a second independent mechanism by which the compound supports retinal health. However, this connection remains speculative without further targeted mechanistic studies and should not be extrapolated to clinical recommendations.
🛒 Where to Buy TUDCA
- Toniiq Ultra High Purity TUDCALab-tested / studied
capsules, 500 mg per capsule, 60 capsules — Claims 98%+ purity verified by HPLC; publishes batch-specific COAs; higher per-capsule dose suits users targeting 500–1000 mg/day protocols - Nutricost TUDCA 250mg
capsules, 250 mg per capsule, 60 capsules — High-volume seller; non-GMO and gluten-free labeling; no third-party purity COA publicly posted, but consistent community reputation for accurate dosing - Double Wood Supplements TUDCA 250mg
capsules, 250 mg per capsule, 60 capsules — USA-manufactured; publishes basic COA on request; popular among biohacker community for reliable potency at accessible price point - Nootropics Depot TUDCA Powder
powder, 250 mg per 1/4 tsp (approximate), 30 g — Best cost-per-gram option for daily high-dose users; same batch-tested material as their capsule line; requires milligram-accurate scale for precise dosing
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
All evidence for TUDCA in retinal degeneration comes from preclinical animal studies; no large human randomized trials have established efficacy or safety for this indication, and TUDCA is not an approved retinal therapy. TUDCA is contraindicated in bile duct obstruction and requires medical supervision in patients with gallbladder disease, cholangitis, or hepatic impairment; it may also interact with cyclosporine, bile acid sequestrants, and certain lipid-lowering medications.
Frequently Asked Questions
What types of retinal degeneration have been studied with TUDCA in animal models?
Preclinical research has examined TUDCA in models of retinitis pigmentosa caused by Pde6b mutations in rd1 [9] and rd10 mice [2], P23H rhodopsin mutation in transgenic rats [4], RPGR-related X-linked RP in knockout mice [10], acute retinal detachment [5], and Leber congenital amaurosis as a theoretical target [6]. Each model represents a distinct genetic or injury cause of photoreceptor death.
How does TUDCA's approach differ from gene therapy for retinal degeneration?
Gene therapy aims to correct or replace a specific defective gene, making it mutation-specific by design. TUDCA acts downstream on common cell death pathways — primarily ER stress and mitochondrial apoptosis — that are activated across many different genetic mutations [1]. This downstream, mutation-agnostic mechanism is sometimes described as a neuroprotective strategy that could theoretically complement mutation-targeted approaches, though no combination studies in humans exist.
Does TUDCA protect cone photoreceptors specifically, or only rods?
Most early studies focused on rod preservation because rods degenerate first in most inherited retinal dystrophies. However, at least one study directly examined cone rescue, finding that subcutaneous TUDCA delivery could rescue cone photoreceptors in a degenerative retina model [11]. Cone preservation is clinically important because central and color vision depend on cone function, and secondary cone loss after rod degeneration is a major driver of disability.
Could TUDCA be useful after retinal detachment surgery?
In an experimental retinal detachment model, TUDCA reduced photoreceptor apoptosis compared with untreated animals [5], suggesting potential to limit cell death during the detachment window. A 2026 review also discussed anti-apoptotic agents as a promising adjunct to surgical repair in retinal detachment [12]. Whether this effect translates into better visual outcomes after human retinal detachment surgery remains an open and unstudied question.
What is the MerTK pathway, and why does TUDCA's effect on it matter?
MerTK is a tyrosine kinase receptor on RPE cells that triggers the daily engulfment of shed photoreceptor outer segments; when MerTK is mutated or dysfunctional, outer segment debris accumulates and photoreceptors eventually die. TUDCA has been shown to activate MerTK and enhance RPE phagocytosis [7], suggesting that part of its protective effect may be indirect — by keeping the RPE functional rather than acting solely on photoreceptors themselves.
Are there human clinical trials of TUDCA for retinal degeneration?
No large-scale randomized controlled trials of TUDCA specifically for retinal degeneration in humans have been published in the evidence reviewed here. All the studies summarized above are animal model experiments. TUDCA is approved or widely used for certain liver and bile duct conditions in some countries, but its application to retinal indications remains investigational. Patients with any form of retinal degeneration should discuss supplement use with their treating ophthalmologist before starting.
References
- Boatright JH et al. Tool from ancient pharmacopoeia prevents vision loss. Molecular vision (2006). PMID 17213800
- Phillips MJ et al. Tauroursodeoxycholic acid preservation of photoreceptor structure and function in the rd10 mouse through postnatal day 30. Investigative ophthalmology & visual science (2008). PMID 18436848
- Oveson BC et al. Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degeneration. Journal of neurochemistry (2011). PMID 21054389
- Fernández-Sánchez L et al. Tauroursodeoxycholic acid prevents retinal degeneration in transgenic P23H rats. Investigative ophthalmology & visual science (2011). PMID 21508111
- Mantopoulos D et al. Tauroursodeoxycholic acid (TUDCA) protects photoreceptors from cell death after experimental retinal detachment. PloS one (2011). PMID 21961034
- Fu Y et al. Pathophysilogical mechanism and treatment strategies for Leber congenital amaurosis. Advances in experimental medicine and biology (2014). PMID 24664772
- Murase H et al. TUDCA Promotes Phagocytosis by Retinal Pigment Epithelium via MerTK Activation. Investigative ophthalmology & visual science (2015). PMID 25804419
- Fernández-Sánchez L et al. Natural Compounds from Saffron and Bear Bile Prevent Vision Loss and Retinal Degeneration. Molecules (Basel, Switzerland) (2015). PMID 26263962
- Lawson EC et al. Tauroursodeoxycholic Acid Protects Retinal Function and Structure in rd1 Mice. Advances in experimental medicine and biology (2016). PMID 26427442
- Zhang X et al. Disease mechanisms and neuroprotection by tauroursodeoxycholic acid in Rpgr knockout mice. Journal of cellular physiology (2019). PMID 30924157
- Tao Y et al. Subcutaneous delivery of tauroursodeoxycholic acid rescues the cone photoreceptors in degenerative retina: A promising therapeutic molecule for retinopathy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2019). PMID 31387173
- Behar-Cohen F et al. Neurodegeneration and neuroprotection in retinal detachment. Handbook of clinical neurology (2026). PMID 42217976
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
